MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Transcriptome-microRNA correlation and the regulation of targeted gene expression in de novo Parkinson’s disease patients.

    KE. Choi, SY. Kim, J. Jang, I. Hwang, KW. Lee, JS. Kim (Seoul, Republic of Korea)

    Objective: To conduct a case-control study in single, comprehensive movement disorder center in Seoul. Background: Parkinson’s disease (PD) is the second most common neurodegenerative disease…
  • 2023 International Congress

    A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data

    T. Nikolcheva, G. Pagano, N. Pross, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Seppi, A. Monnet, N. Shariati, L. Rutten-Jacobs, S. Zanigni, T. Kustermann, K. Taylor, D. Trundell, H. Svoboda, A. Bonni, P. Fontoura, R. Doody (BASEL, Switzerland)

    Objective: The study will evaluate the efficacy and safety of prasinezumab in individuals with early-stage Parkinson's disease (PD) on stable symptomatic therapy. Background: Available treatments…
  • 2023 International Congress

    Quantitative gait analysis to evaluate changes in gait pattern after Botulinum toxin A injection by hemiparesis

    M. Pinter, M. Petrovicsova, Y. Teuschl, A. Dachenhausen, K. Matz, C. Bancher (Krems, Austria)

    Objective: This retrospective study aimed to assess the effect of Botulinum toxin A (BoNT-A) injections in the lower limbs of hemiparetic patients on gait parameters,…
  • 2023 International Congress

    An European-Canadian multinational evaluation of access to care in Parkinson disease: a patient perspective

    M. van Munster, E. Crighton, A. Sánchez-Ferro, J. Ferreira, R. Bouça, E. Ruzicka, D. Pedrosa, D. Grimes, T. Mestre (Marburg, Germany)

    Objective: To provide a multi-national perspective of people with Parkinson disease (PwPD) on access to healthcare and the impact of the COVID-19 pandemic on those…
  • 2023 International Congress

    Dystonia in the Middle East – The Cleveland Clinic Abu Dhabi Experience

    S. Mansoor, K. Waqar, M. Thomas, S. Mittal (Abu Dhabi, United Arab Emirates)

    Objective: This study aimed to evaluate the clinical spectrum of patients with dystonia seen at Cleveland Clinic Abu Dhabi Hospital (CCAD), a tertiary care center…
  • 2023 International Congress

    Enhanced sensitivity to bradykinesia progression using digital health technologies in early Parkinson’s disease

    M. Czech, L. Yang, J. Shen, D. Badley, M. Crouthamel, T. Kangarloo, R. Dorsey, J. Adams, J. Cosman (North Chicago, USA)

    Objective: To evaluate the sensitivity of digital biomarkers of bradykinesia to longitudinal progression relative to MDS-UPDRS sub-scores in early-stage Parkinson’s disease (PD). Background: It is…
  • 2023 International Congress

    Predictors of death in Parkinson’s disease

    M. Garon, L. Weis, F. Pistonesi, V. Cianci, N. Cazzola, ML. Nasi, R. Biundo, A. Antonini (padova, Italy)

    Objective: To investigate how clinical, motor and behavioural characteristics impact on Parkinson mortality in a cohort from a tertiary movement disorders specialty center . Background:…
  • 2023 International Congress

    Paraneoplastic cerebellar degeneration due to an anti-SOX 1 antibody manifesting as head tremors, without evidence of underlying malignancy

    K. Sai Krishna, F. Mustafa, R K. Singh, A. Das, B. Mishra, A. Elavarsi, D. Vibha, M. Tripathy, S. Gaikwad (NEW DELHI, India)

    Objective: To describe a case of Paraneoplastic Cerebellar degeneration (PCD) linked to anti-SOX 1 antibody with no discernible malignancy. Background: PCD is a rare neurological…
  • 2023 International Congress

    Actigraphy wear compliance across CNS disorders

    J. Lavine, A. Pearlmutter, K. Momeni, R. Ellis (New York, USA)

    Objective: Examine actigraphy wear compliance in 5 neurological-disorders clinical trials using an ActiGraph GT9X Link with additional compliance features Background: Wrist worn biometric devices are…
  • 2023 International Congress

    Gene rearrangement as the cause of hereditary Hypomyelinating Leukodyistrophy disease type 5 (HLD5)

    A. Menéndez-Albarracín, P. Pastor-Muñoz, K. Beyer, M. Gea-Rispal, D. Vilas-Roldán, R. Alvarez-Ramo, L. Ispierto-González (Barcelona, Spain)

    Objective: To define the clinical, neurophysiological, neuroimaging and pathological findings from a patient carrying a FAM126A homozygous exon 3-7 deletion. Background: Hypomyelinating leukodystrophies constitute a…
  • « Previous Page
  • 1
  • …
  • 89
  • 90
  • 91
  • 92
  • 93
  • …
  • 186
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley